RBX 7455

Drug Profile

RBX 7455

Alternative Names: RBX7455

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Rebiotix
  • Class Antibacterials; Bacteria; Probiotics
  • Mechanism of Action Immunomodulators; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Clostridium infections

Most Recent Events

  • 01 Nov 2016 Phase-I clinical trials in Clostridium infections in USA (PO) (NCT02981316)
  • 11 Oct 2016 Rebiotix has patent protection for microbiota restoration therapy in USA, Australia and Canada
  • 20 Jul 2016 Rebiotix submits a Master File with the US FDA in USA for Clostridium infections (before July 2016; Rebiotix website, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top